Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

DMPI Insider Trading

TuHURA Biosciences, Inc./NV | Pharmaceutical Preparations

Comprehensive Trading Performance Summary

The investment history of corporate insiders at TuHURA Biosciences, Inc./NV provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2019-09-20 00:45 2019-09-13 Bell John K Director BUY $0.68 35,000 $23,744 35,000 +100.0%
2019-09-16 23:22 2019-09-13 Bell John K Director BUY $0.68 35,000 $23,744 44,701 +360.8%
2017-11-18 00:32 2017-11-15 Bell John K Director BUY $0.81 20,000 $16,200 95,019 +26.7%
2017-11-17 00:30 2017-11-14 Zarrabian Saiid Director, Officer - Interim CEO BUY $0.82 60,900 $50,054 5,900 +100.0%
2017-10-10 15:10 2017-10-06 BACHA JEFFREY Director, Officer - CEO BUY $0.87 10,000 $8,724 63,697 +18.6%
2017-10-06 01:05 2017-10-05 Praill Scott Officer - Chief Financial Officer BUY $0.85 17,500 $14,910 47,366 +58.6%
2017-06-28 18:31 2017-06-26 Cranston Lynda Sarah Director BUY $3.60 2,083 $7,499 2,344 +798.1%
2017-06-28 18:30 2017-06-26 Bell John K Director BUY $3.60 4,167 $15,001 49,455 +9.2%
2017-06-28 18:29 2017-06-26 BACHA JEFFREY Director, Officer - CEO BUY $3.60 6,700 $24,120 53,345 +14.4%
2017-06-28 18:34 2017-06-26 Praill Scott Officer - Chief Financial Officer BUY $3.60 4,167 $15,001 29,444 +16.5%
2017-06-28 18:33 2017-06-26 Mohr Erich Director BUY $3.60 4,167 $15,001 6,110 +214.5%
2017-06-07 18:46 2017-06-06 Bell John K Director BUY $2.12 10,000 $21,200 45,288 +28.3%
2017-06-07 00:12 2017-06-06 BACHA JEFFREY Director, Officer - CEO BUY $2.12 5,000 $10,600 46,645 +12.0%
2017-06-07 00:23 2017-06-06 Praill Scott Officer - Chief Financial Officer BUY $2.10 9,500 $19,950 25,277 +60.2%
2017-05-08 23:58 2017-05-05 BACHA JEFFREY Director, Officer - Chief Executive Officer BUY $2.20 2,500 $5,500 41,645 +6.4%
2017-02-02 19:44 2017-02-01 BACHA JEFFREY Director, Officer - CEO BUY $5.00 4,000 $20,000 38,969 +11.4%
2015-11-30 21:59 2015-11-25 BACHA JEFFREY Director, Officer, 10% owner - CEO, Director BUY $1.47 7,500 $11,025 137,985 +5.7%
2015-10-09 18:38 2015-10-08 BACHA JEFFREY Director, Officer, 10% owner - President, CEO BUY $0.80 3,000 $2,396 130,485 +2.4%
2015-09-22 17:00 2015-09-18 BACHA JEFFREY Director, Officer, 10% owner - President, CEO BUY $0.83 4,000 $3,320 127,485 +3.2%
2015-07-29 04:03 2015-07-25 Brown Dennis M Director, Officer, 10% owner - Chief Scientific Officer BUY $0.60 10,000 $6,000 3,037,542 +0.3%
2015-07-29 03:59 2015-07-25 BACHA JEFFREY Director, Officer, 10% owner - President, CEO BUY $0.60 10,000 $6,000 123,485 +8.8%
2015-07-23 20:11 2015-07-22 Brown Dennis M Director, Officer, 10% owner - Chief Scientific Officer BUY $0.60 75,000 $45,000 3,027,542 +2.5%
2015-07-17 17:26 2015-07-16 Bell John K Director BUY $0.60 50,000 $30,000 137,000 +57.5%
2015-07-17 17:25 2015-07-16 Garner William J Director BUY $0.60 16,666 $10,000 2,415,207 +0.7%
2015-07-16 14:05 2015-07-16 BACHA JEFFREY Director, Officer, 10% owner - President, CEO BUY $0.60 50,000 $30,000 113,485 +78.8%
2015-07-16 14:07 2015-07-16 Praill Scott Officer - Chief Financial Officer BUY $0.60 50,000 $30,000 60,000 +500.0%
2015-01-22 20:32 2015-01-22 BACHA JEFFREY Director, Officer - CEO and President BUY $0.66 7,500 $4,925 63,485 +13.4%
2014-12-10 23:47 2014-12-09 BACHA JEFFREY Director, Officer, 10% owner - CEO and President BUY $0.90 2,500 $2,250 55,985 +4.7%
2014-11-27 03:33 2014-11-26 BACHA JEFFREY Director, Officer, 10% owner - CEO and President BUY $0.92 2,500 $2,300 53,485 +4.9%
2014-11-24 16:54 2014-11-21 Bell John K Director BUY $0.95 8,000 $7,600 87,000 +10.1%
2014-09-19 20:39 2014-09-18 BACHA JEFFREY Director, Officer - CEO and President BUY $0.98 4,000 $3,920 50,985 +8.5%
2014-09-16 15:43 2014-09-15 BACHA JEFFREY Director, Officer, 10% owner - CEO and President BUY $0.75 4,985 $3,739 46,985 +11.9%
2014-09-10 18:08 2014-09-08 Bell John K Director BUY $0.71 7,000 $4,970 79,000 +9.7%
2014-09-05 22:39 2014-09-04 Bell John K Director BUY $0.78 8,000 $6,237 72,000 +12.5%
2014-03-20 23:35 2014-03-18 Bell John K Director BUY $1.30 25,000 $32,500 44,000 +131.6%
2014-03-20 23:31 2014-03-18 TOTH ROBERT JOSEPH JR Director BUY $1.30 25,000 $32,500 43,500 +135.1%
2014-03-20 23:28 2014-03-18 Brown Dennis M Director, Officer, 10% owner - Chief Scientific Officer BUY $1.30 10,000 $13,000 2,952,542 +0.3%
2014-03-20 23:38 2014-03-18 BACHA JEFFREY Director, Officer, 10% owner - CEO and President BUY $1.30 10,000 $13,000 42,000 +31.3%
2014-03-20 23:34 2014-03-18 Garner William J Director SELL $1.30 80,000 $104,000 10,000 -88.9%
2014-03-20 23:31 2014-03-18 Praill Scott Officer - CFO BUY $1.30 10,000 $13,000 10,000 +100.0%
2014-03-05 04:30 2014-03-04 Brown Dennis M Director, Officer, 10% owner - Chief Scientific Officer BUY $1.56 5,000 $7,808 2,942,542 +0.2%
2014-02-22 03:10 2014-02-21 BACHA JEFFREY Director, Officer, 10% owner - CEO and PRESIDENT BUY $1.00 5,000 $5,000 32,000 +18.5%
2014-02-14 01:05 2014-02-13 BACHA JEFFREY Director, Officer, 10% owner - CEO and PRESIDENT BUY $0.80 5,000 $4,000 27,000 +22.7%
2014-02-12 21:40 2014-02-11 Bell John K Director BUY $0.83 9,000 $7,504 19,000 +90.0%
2014-02-07 21:16 2014-02-05 TOTH ROBERT JOSEPH JR Director BUY $0.88 9,000 $7,920 18,500 +94.7%
2014-02-04 18:12 2014-01-31 TOTH ROBERT JOSEPH JR Director BUY $0.87 2,000 $1,740 9,500 +26.7%
2014-01-31 20:59 2014-01-29 TOTH ROBERT JOSEPH JR Director BUY $0.91 7,500 $6,825 7,500 +100.0%
2013-09-23 14:19 2013-09-20 Garner William J Director BUY $1.00 5,000 $5,000 5,000 +100.0%
SHOW ENTRIES

How to Interpret $DMPI Trades

Not every insider transaction in TuHURA Biosciences, Inc./NV is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $DMPI shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for DMPI

Insider activity data for TuHURA Biosciences, Inc./NV is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $DMPI, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.